Highlights from the Week of 05th October – 12th October in the world of pharma and healthcare!

Highlights from the Week of 05th October 2026 - 12th October 2026 ( FDA, Approval ) FDA approves Genentech's TECENTRIQ and TECENTRIQ HYBREZA in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA dMMR colon cancer ( FDA, Approval ) Healio obtains FDA approval of HOVILPRI to treat mucocutaneous lesions of herpes simplex virus in immunocompromised adults with no previous therapy response ( FDA, Approval ) Teva receives FDA approval of WELTRUZA for extended-release injectable suspension, to treat schizoprenia in adults ( FDA, Approval ) Pfizer's TUKYSA, in combination with trastuzumab and pertuzumab receives FDA approval for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2+ breast cancer Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Connect with us

Please fill in the information below, and we'll get back to you.